CytoAgents, Inc

CytoAgents is focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS). At the helm is CEO Teresa Whalen, RPh, a biotech innovator, life sciences investor, and clinical pharmacist with a successful track record of bringing life-changing healthcare products to market. She leads a team of world-renowned clinical drug development experts and scientific advisory board members. Meet the CytoAgents team here: https://lnkd.in/g7P29x3i #biotechnology #biotech #healthcareleadership #leadership #crs

Cytokine Release Syndrome (CRS) is an overreaction of the immune system caused by excessive, prolonged cytokine production. CRS can be triggered by a wide range of indications, including modern immunotherapies such as CAR T-cell therapy. CytoAgents’ approach to treating CRS focuses on rebalancing the immune system by reducing the destructive impact of excessive cytokines while leaving necessary immune functions intact. Learn more here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

As CAR T-cell therapy continues to improve outcomes for patients with certain types of cancers, researchers are focusing on improving the safety of this revolutionary form of treatment. One major area of concern is a potentially life-threatening side effect known as Cytokine Release Syndrome (CRS) – an overreaction of the immune system. CytoAgents is developing an effective treatment for CRS, which will make CAR T-cell therapy safer for patients. Learn about CRS and CytoAgents' solution here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

CytoAgents' drug candidate CTO1681 has the ability to modulate the cytokine response, making it a promising candidate to mitigate Cytokine Release Syndrome (CRS), a common side effect of CAR T-cell therapy in oncology. CTO1681 reduces the cytokines generated during CRS while enabling the body to maintain appropriate cytokine levels. Reducing the rates and severity of toxicity allows for the treatment of more patients, treatment in the outpatient setting, and the decrease of treatment-related morbidity. Learn more: https://lnkd.in/ewGhjzRW #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

Scientists and healthcare professionals are continually seeking ways to improve?chimeric antigen receptor (CAR) T-cell therapy for the treatment of patients with certain types of cancer. Other researchers are focused on creating solutions to make this innovative form of treatment safer for patients. CytoAgents is developing a treatment for a common and potentially life-threatening side effect of CAR T-cell therapy known as Cytokine Release Syndrome (CRS). Learn about our solution here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

Earlier this year, CytoAgents received another grant from The National Institutes of Health to accelerate the development of its lead drug candidate, CTO1681, designed to prevent and mitigate Cytokine Release Syndrome (CRS) in patients receiving CAR T-cell therapy. CEO Teresa Whalen, RPh commented: “We are appreciative of the support from the National Cancer Institute of the National Institutes of Health, this funding will help to accelerate our ongoing trial. Effective CRS treatment will not only improve patient outcomes, but also expand patient access to these important, new cancer treatment modalities.” Learn more about CRS and CytoAgents here: https://lnkd.in/eyd7hsFe #biotechnology #healthcareleadership #cytokinereleasesyndrome #crs

More than two-thirds of CAR T-cell therapy patients suffer from Cytokine Release Syndrome (CRS) as a side effect of their treatment. CytoAgents' drug candidate has the ability to modulate the cytokine response, making it a promising solution to mitigate this condition. Learn more here: https://lnkd.in/eFasArrf #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

While CAR T-cell therapy is a game-changing treatment for some cancer patients, it comes with significant risks. More than two-thirds of CAR T-cell therapy patients experience a potentially life-threatening side effect known as Cytokine Release Syndrome (CRS), which is an overreaction of the immune system. Learn about CytoAgents' solution to CRS here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

Led by CEO Teresa Whalen, RPh, CytoAgents is a clinical-stage biotechnology company, dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS). Through Teresa's leadership, CytoAgents has secured funding from The National Institutes of Health and is enrolling patients in a Phase 1b/2a clinical trial evaluating CTO1681 to treat CRS in lymphoma patients receiving CAR T-cell therapy. Learn more about CytoAgents here: https://cytoagents.com/ #biotechnology #biotech #healthcareleadership #cytokinereleasesyndrome

Cytokines play a critical role in enabling the immune system to protect the body from diseases and other sources of potential injury. Immune cells produce cytokines to activate and recruit other immune cells to help eliminate threats. These immune cells in turn produce their own cytokines to amplify this signal, recruiting more cells and creating a feedback loop resulting in a targeted inflammatory response. Normally, the body balances this inflammatory response with a series of anti-inflammatory measures which downregulate the production of cytokines thereby restoring homeostasis. In the absence of adequate negative regulation, cytokine production and activation can spiral out of control, causing excessive systemic inflammation and leading to the dangerous condition of Cytokine Release Syndrome (CRS). CytoAgents’ approach to treating CRS focuses on rebalancing the immune system by reducing the destructive impact of excessive cytokines while leaving necessary immune functions intact. Learn more: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines Teresa Whalen, RPh